Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from TuHURA Biosciences ( (HURA) ).
TuHURA Biosciences, Inc. is making significant strides in cancer immunotherapy with its IFx-2.0 technology, set to undergo a Phase 3 trial in advanced Merkel Cell Carcinoma. The company has entered a non-binding letter of intent to acquire Kineta’s innovative VISTA inhibiting antibody, KVA12123, to enhance its treatment pipeline. TuHURA’s strategic advancements include novel bi-specific antibodies and mRNA technologies, aiming to overcome resistance to current cancer immunotherapies. Key leadership hires aim to bolster clinical and operational execution as the company targets ambitious milestones for 2024-2025.
Learn more about HURA stock on TipRanks’ Stock Analysis page.